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Abstract
Background: Patients with advanced cancer for whom standard systemic treatment is no longer available may be
offered participation in early phase clinical trials. In the decision making process, both medical-technical information
and patient values and preferences are important. Since patients report decisional conflict after deciding on
participation in these trials, improving the decision making process is essential. We aim to develop and evaluate an
Online Value Clarification Tool (OnVaCT) to assist patients in clarifying their values around this end-of-life decision.
This improved sharing of values is hypothesized to support medical oncologists in tailoring their information to
individual patients’ needs and, consequently, to support patients in taking decisions in line with their values and
reduce decisional conflict.
Methods: In the first part, patients’ values and preferences and medical oncologists’ views hereupon will be
explored in interviews and focus groups to build a first prototype OnVaCT using digital communication (serious
gaming). Next, we will test feasibility during think aloud sessions, to deliver a ready-to-implement OnVaCT. In the
second part, the OnVaCT, with accompanied training module, will be evaluated in a pre-test (12–18 months before
implementation) post-test (12–18 months after implementation) study in three major Dutch cancer centres. We will
include 276 patients (> 18 years) with advanced cancer for whom standard systemic therapy is no longer available,
and who are referred for participation in early phase clinical trials. The first consultation will be recorded to analyse
patient-physician communication regarding the discussion of patients’ values and the decision making process.
Three weeks afterwards, decisional conflict will be measured.
Discussion: This project aims to support the discussion of patient values when considering participation in early
phase clinical trials. By including patients before their first appointment with the medical oncologist and recording
that consultation, we are able to link decisional conflict to the decision making process, e.g. the communication
during consultation. The study faces challenges such as timely including patients within the short period between
referral and first consultation. Furthermore, with new treatments being developed rapidly, molecular stratification
may affect the patient populations included in the pre-test and post-test periods.
Trial registration: Netherlands Trial Registry number: NTR7551 (prospective; July 17, 2018).
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Background
Most patients with advanced cancer will ultimately reach
the moment that standard anti-cancer therapy is no lon-
ger available. At that particular moment, some are still
in a relatively good condition and may live for several
months or longer. Those patients may be asked and/or
considered to participate in early phase clinical trials.
These trials are a major prerequisite for the further
development of efficacious anti-cancer therapies. Despite
improved molecular stratification for experimental ther-
apy and thus improved anti-cancer activity in these
clinical trials [1], the majority of patients do not benefit
from participation. Although a recent search revealed a
19.8% response rate (both complete and partial responses)
in phase I trials from 2014 until mid-2015 [2], it is known
that participation can (also) be beneficial for other
reasons. Hope for and belief in benefit are for instance im-
portant reasons for patients to participate [3, 4], and those
factors can positively affect quality of life [5]. However, it
is also known that patients can be aware of palliative care
services at the end of life but may not consider them for
themselves [6], which may especially apply to those who
have unrealistic hope for benefit [4]. In that case, trial
participation may interfere with adequate end-of-life
decision making.
Deciding whether or not to participate in an early phase
clinical trial thus is a complex decisional process. Deci-
sional conflict, i.e. “the extent to which they [i.e. patients]
report unresolved decisional needs such as personal
uncertainty and related deficits in knowledge, values clar-
ity, and support or pressure” [7, p69] has been found in
patients after deciding on participation in an early phase
clinical study [7], which seems to indicate that the current
decision making process could be improved. Improving
patients’ decision making process, independent from the
ultimate content of the decision, has shown to be a way to
improve health-related quality of life [8, 9]. Easing this
major-impact decision therefore offers an opportunity to
improve quality of life for these patients.
Important factors to optimize the decision making
process are defining personal values and weighing the
available information on the proposed interventions [10].
In the consent procedure preceding clinical trial participa-
tion, patients’ values and preferences together with more
technical information need to be discussed. Systematic
reviews and empirical research suggest that effective
doctor-patient communication requires knowledge about
values and preferences of patients [11, 12]. However, given
the complexity of early phase clinical trials nowadays,
focus on the information about the specific clinical trial
(s) may prevail with a limited patient-physician discussion
on patient values. Furthermore, information on actual
prognosis and available palliative care options are not
always given [13, 14]. Incomplete information provision
may cause unmet communication needs [12], which sup-
ports the hypothesis that effective decision making for trial
participation could benefit from more focus on patients
values and preferences. However there is a lack of studies
that investigate potential interventions to improve this
aspect [12]. Improving patient-oncologist communication
into a more patient-based and value-centred dialogue
could potentially be achieved through focussing on true
“human connection” [15].
Decision aids can offer support in this complex decision
making process. Although not investigated in the context
of participation in early phase clinical trials, the use of
decision aids in other medical situations has been found
to improve patient-provider communication and reduce
decisional conflict [16]. However, decision aids do not
particularly focus at the previously mentioned human
connection. Eliciting patients’ values and preferences bet-
ter reflects this connection and is a key part of the shared
decision making process in widely used shared decision
making models [17–19]. Therefore, according to the
International Patient Decision Aid Standards (IPDAS), the
inclusion of value clarification in decision aids is strongly
recommended [20]. Indeed, exposure to a decision aid
with explicit value clarification resulted in a higher pro-
portion of patients choosing an option congruent with
their values [16]. This suggests that singly clarifying one’s
values could already improve the decision making process.
In particular, value clarification needs to be attuned to a
personal logic that is based on context in order not to be
burdensome [21].
We will develop an online value clarification tool
(OnVaCT) with accompanying training to help patients
explore their own values and attitudes towards palliative
care and treatment within an early phase clinical trial in
order to incorporate this information in the patient-
oncologist communication. We will evaluate the OnVaCT
by assessing the communication process regarding the
extent to which caregivers involve patients in the decision
making process and the patients’ decisional conflict. We
hypothesize that clarifying patients’ values in preparing for
the first consultation with a medical oncologist (i.e. the
consultation that sets the consent procedure in motion)
will help patients to more easily share their personal
values with their medical oncologist. In turn, these
insights may assist oncologists in aligning the information
offered with the values considered important by patients.
Ultimately, we hypothesize that this intervention will
reduce decisional conflict.
Methods
Overall aim
The overall aim of the project is to study whether a pre-
paratory online value clarification tool decreases decisional
conflict in patients who are considering participation in
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early phase clinical trials, by improving patient-physician
communication with respect to the discussion of patients’
preferences and the decision making process. Following the
Medical Research Council – UK – guideline for complex
interventions [22], the study consists of two major parts
that take place simultaneously, as illustrated in Fig. 1:
1. the development and feasibility testing of the
OnVaCT (phase 1 and 2 of MRC framework);
2. the implementation and evaluation of the OnVaCT
(phase 3 and 4 of MRC framework).
Setting
Patients will be included from three Dutch hospitals
with sizeable units for early phase clinical research:
– Erasmus MC, Rotterdam;
– Netherlands Cancer Institute – Antoni van
Leeuwenhoek hospital, Amsterdam;
– UMC Utrecht.
Part 1: development and feasibility testing of the OnVaCT
Aims
1. To qualitatively study life values of patients facing
participation in early phase clinical trials.
2. To design and test an OnVaCT that fits the
decision-making processes of patients and working
and communication routines of oncologists, thereby
supporting patient-physician communication.
Study design
The following main phases will be distinguished:
1. development (identifying existing theoretical and
empirical evidence; collecting additional evidence;
modelling of the tool);
2. feasibility testing/piloting of the modelled OnVaCT.
Information will be gathered prospectively using inter-
views, focus groups and user sessions with the modelled
OnVaCT.
Study population
We will include patients with advanced cancer who face
the choice whether or not to participate in early phase
clinical trials, because standard systemic therapy is not or
no longer available for them. Inclusion and exclusion
criteria for patients are shown in Table 1. In addition,
patient representatives (i.e. an advisory council of patients
and relatives) of the Consortium on Palliative Care
Southwest Netherlands and healthy subjects (e.g. co-
workers) will be involved in the feasibility and pilot
testing phase.
To make the OnVaCT meaningful to both patients
and medical oncologists, we will also include medical
oncologists in the development and pilot testing phase
of the study. Medical oncologists and fellow medical
oncologists must be a member of the early phase clinical
research teams of the participating hospitals to be
eligible to participate.
Procedures
Development phase: clarifying life values through
semi-structured interviews Patients will undergo two
serial semi-structured interviews about their life values,
which will be (partially) based on a literature search for
existing theoretical and empirical evidence. The first
interview will take place before the first consult with a
medical oncologist about early phase clinical trials. The
second interview, which will follow-up on the results
from the first interview, will take place approximately 3
weeks after the patient has had their first consultation
about early phase clinical trials. Serial interviewing is
chosen to neatly fit the evolving and complex decision
process of the patient, and to generate “private accounts
Fig. 1 Schematic overview of the OnVaCT project
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and descriptions of sensitive topics” that characterize
this decision process [23].
In addition, medical oncologists from the participating
hospitals will be interviewed via a semi-structured inter-
view about patient-physician interaction, the role of life
values in consultation and about their preferences and
needs for the OnVaCT to be used in daily work.
After analysing the interviews, there will be four focus
groups (i.e. one with patients and three with medical
oncologists) to validate the results of the interviews by
discussing the main values and themes and requirements
and wishes for the OnVaCT that were derived from the
interviews. In addition, tool functionalities and tool design
will be discussed. Patient representatives will also be
involved in the focus groups.
In close collaboration with an ICT company specialized
in the development of electronic educational tools and
serious games, a theoretical basis for the set-up of the
OnVaCT is formulized. The results from the interview
and focus groups analyses will be used by the researchers
and the ICT company to design the content of the
OnVaCT and to further develop the set-up. This will
result in a first prototype.
Feasibility and pilot testing phase For feasibility and
pilot testing, think aloud sessions with patients, medical
oncologists and patient representatives will be organized
in which the prototype OnVaCT will be tested and feed-
back will be registered for further improvement of the
OnVaCT. A think aloud session is a method in which
subjects perform search, evaluation and application tasks
within an online interface while thinking aloud and giving
feedback [24]. The think aloud sessions will be individual
and the patient sessions will differ and be analysed separ-
ately from the oncologists sessions, as the two groups have
different needs and interests regarding the OnVaCT.
In this phase, the collaboration with the ICT company
will be intensified. To maximize the input of feedback on
the OnVaCT functionalities and design, also healthy
subjects (e.g. co-workers) will be asked to test the
OnVaCT for usability and bug detection on a voluntary
base. Based on the results, the OnVaCT will be adapted,
and a ready-to-implement OnVaCT will be delivered.
Purposeful sampling
Based on research on the calculation of sample sizes for
qualitative interviewing [25], purposeful sampling will
require a total of 24 serial interviews with 12 patients (or
less if saturation – i.e. the interviews no longer provide
new insights – is reached). Knowing that a small number
of oncologists are collaborating in the three participating
early phase clinical research units, we will aim for 2–3
semi-structured interviews per unit (n = 6–8 in total).
The total number of patients, representatives and
relatives participating in the patient focus group might
fluctuate due to the natural courses of the diseases/
treatments, but we aim for the focus group to contain
6–8 individuals with a range in patient characteristics.
There will be three focus groups with medical oncol-
ogists (in training), each in one of the participating
hospitals with an early phase clinical research unit
and consisting of 3–4 oncologists.
The think aloud sessions for piloting of the value clarifi-
cation tool will be conducted with patients (n = 8–10) and
with medical oncologists (n = 6). Also healthy subjects and
patient representative (s) will be asked to participate in
this phase; the number of participants depends on the
developmental process. The test sessions with healthy
subjects, primarily take place for usability purposes, but
may also reveal some additional insights regarding the
(presentation of the) content of the tool, since they – like
our target patient population – have no prior knowledge
about the tool.
Qualitative analysis
This study will provide a qualitative thematic analysis [26]
of the gathered data. The patient and oncologist inter-
views will be audio taped and transcribed verbatim, and
uploaded to Atlas.ti 8.3.20. A bottom-up approach will be
applied that allows for the extraction of general themes
and patterns from raw material [27–29]. Focus groups will
be both audio- and videotaped and transcribed verbatim.
Think aloud sessions will be videotaped for the analysis
and summarization of the testing of the content, usability
and user experience of the OnVaCT.
The transcripts from the interviews will first be open
coded to label data, then axial coded to categorize the
Table 1 Inclusion and exclusion criteria for patients
Inclusion criteria Exclusion criteria
* Diagnosed with advanced cancer and eligible for first participation in an early
phase clinical trial
* Cognitive impairment (e.g. dementia) according to the
medical record
* Aged 18 years or older
* Sufficient command of the Dutch language Additional exclusion criteria for part 2:
* Written informed consent * No access to the Internet
* Participated in interviews regarding the development of the
OnVaCT
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labelled data, creating a coding scheme accompanied by
memos. The analysis is cyclic, meaning that with every ana-
lysis of an interview, the coding scheme with its key con-
cepts, underlying themes, subthemes and explanatory
memos will be further completed with the necessary
nuances. Analysis of the focus groups will be done in a
similar manner as the interviews. Special attention will be
paid to the themes and values emerging from the interview
study and whether they are recognized by patients partici-
pating in the focus group. During the focus groups with
medical oncologists, the reaction and mutual interaction
about the impact the OnVaCT might have on daily prac-
tices will also receive special attention. Lastly, think aloud
sessions will be analysed to assess usability and perceived
usefulness [24]. For the assessment of usability, we will
especially focus on the person’s ability to navigate and find
the desired information and his ideas on the layout. Per-
ceived usefulness is about the content presented in the
OnVaCT in terms of comprehension, presentation of the
content, and the applicability of the content to the patient.
Part 2: implementation and evaluation of the OnVaCT
Aims
1. To evaluate the effect of implementation of the
OnVaCT with accompanying training on:
a. patients’ decisional conflict (primary outcome);
b. patient-physician communication regarding the
discussion of patients’ preferences and the
decision making process (secondary outcome).
2. To investigate the actual usage of the OnVaCT
(secondary outcome).
Study design
To evaluate the OnVaCT, we will perform a prospective
pre-test post-test multi-centre clinical study to investigate
the effect of implementation of the OnVaCT (Fig. 1). In
the period between pre-test and post-test the OnVaCT
will be implemented. Results on decisional conflict and
patient-physician communication measured during the
first period of 12–18months before implementation of
the OnVaCT (pre-test) will be compared with the results
measured during a second period of 12–18months after
implementation (post-test). In both the pre-test and the
post-test data will be collected at three time points:
T1.before the actual visit to the unit for early phase
clinical research: registration of baseline
characteristics;
T2. the initial visit with a medical oncologist regarding
early phase clinical studies: measurement of patient-
physician communication;
T3. three weeks after T2: measurement of decisional
conflict.
Study population
Similar to part 1, we will include patients with advanced
cancer who face the choice whether or not to participate
in early phase clinical trials, because standard systemic
therapy is not or no longer available for them (Table 1).
Additionally, patients need to have access to the Internet
and patients included in part 1 are excluded for part 2 of
the project.
Procedures
Implementation phase When the members of the
project team agree on the content of the OnVaCT, we will
develop a training session for the medical oncologists of
the early phase clinical research units. All members of the
study teams will be informed about the forthcoming im-
plementation of the tool and trained how to handle the
preparatory work of the patient by using the tool and how
to integrate patients’ values and preferences and further
information needs in the communication with patients
facing a choice whether or not to participate in an early
phase clinical trial. We will use the barriers as perceived
by caregivers of the team as explored during the develop-
ment of the OnVaCT as input for the development of the
accompanying training module. The module will be devel-
oped in close collaboration with a psychologist with
educational experience, and based on previously devel-
oped training modules in e.g. the VOICE study, in which
clinicians were trained in exploring patients’ preferences
and how to use a preparatory tool during consultations
[30], and the CHOICE trial, in which a training was devel-
oped on shared decision making in consultations about
palliative care, specifically for oncologists [31].
Directly after the training, the OnVaCT will be imple-
mented in clinical practice, and the post-test will start.
Patients in the post-test will use the tool in preparation of
their first visit to a medical oncologists regarding early
phase clinical trials.
Evaluation phase (pre-test and post-test) After giving
preliminary oral consent for participation in this study,
patients will receive a link to the first questionnaire (T1)
via e-mail, which they have to complete before the initial
visit with the medical oncologist (T2). The questionnaire
starts by asking if the patient gives his/her consent to par-
ticipate in that particular questionnaire. In the post-test,
an additional question will ask whether the patient under-
stands and agrees that data from the OnVaCT will be
shared with the oncologist with whom he/she has an
appointment. After finishing the first questions, patients
participating in the post-test will receive a direct link to
the OnVaCT and additional questions regarding technol-
ogy acceptance and satisfaction with the tool. During both
the pre-test and the post-test, written informed consents
Lent et al. BMC Palliative Care          (2019) 18:106 Page 5 of 10
will be signed and/or collected immediately before the
initial visit with the medical oncologist (T2). Subsequently,
the initial consultation itself (T2) will be (video- and)
audiotaped. Decisional conflict will be measured by means
of a final questionnaire 3 weeks after the initial consult
with a study medical oncologist (T3).
Measurements
Table 2 gives an overview of the baseline and outcome
measurements in part 2 of the OnVaCT project.
Baseline measurements The background questionnaire
for the evaluation of the OnVaCT contains socio-
demographic items on age, gender, education, living situ-
ation, computer experience and online-surfing behaviour.
Medical background characteristics (e.g. diagnosis, time
since diagnosis, health status, WHO performance status)
will be collected from the medical file. In addition, several
potential confounding factors will be measured (see also
Table 2):
– patients’ health literacy;
– sense of hope;
– technology acceptance (only in post-test);
– satisfaction with the tool (only in post-test);
– quality of life.
Outcome measurements The primary outcome (Table 2)
is decisional conflict, i.e. the extent to which patients feel
insecure about their decision regarding participation in
early phase clinical trials. Secondary outcomes (Table 2) are
the communication process (consisting of the extent to
which caregivers involve patients in shared decision-
making; the discussion of patients’ values and preferences;
Table 2 Measurements in part 2 of the OnVaCT project
Outcome Instrument Source
Baseline measurements
Patient’s health literacy Set of Brief Screening Questions (SBSQ-D): Dutch version [32, 33] of the 3-item
health literacy scale of Chew et al. [30] on 5-point Likert scales.
Questionnaire at T1
Sense of hope Herth Hope Index (HHI) [34, 35]: Items on a 4-point Likert scale on three dimensions:
temporality and future, positive readiness and expectancy, and interconnectedness.
Questionnaire at T1
Technology acceptance Measurements from the Technology Acceptance Model (TAM), adapted in the
Unified Theory of Acceptance and Use of Technology (UTAUT) [36–38]. In total, 15
items on a 7-point Likert scale are included.
Questionnaire at T1,
only in post-test
Satisfaction with the tool Website Satisfaction Scale [39–42]: A Dutch version of the Website Satisfaction Scale
will be used, consisting of the subscales ‘satisfaction with comprehensibility’ (3
items), ‘satisfaction with attractiveness’ (5 items) and ‘satisfaction with emotional
support’ (4 items), all on a 7-point Likert scale.
Questionnaire at T1,
only in post-test
Quality of life QLQ-C30 version 3.0 [43] of the European Organisation for Research and Treatment
of Cancer (EORTC): 28 items on a 4-point Likert scale and 2 items on a 7-point Likert
scale.
Questionnaire at T1
Primary outcome
Decisional conflict Decisional Conflict Scale (DCS) [25]: 16 items on a 5-point Likert scale from 0 to 4.
The items are summed, divided by 16 and multiplied by 25 to get a total score for
decisional conflict on a 0–100 scale.
Questionnaire at T3
Secondary outcomes
Extent to which caregivers involve
patients in shared decision-making
Adapted Observer OPTIONMCC [44] based on the OPTION5 [45]: in each recorded
consultation, 7 behavioural competences for the medical oncologists regarding goal
talk (1 item), option talk (2 items), team talk (1 item), decision talk (2 items) and
evaluation talk (1 item) will be coded on a 5-point Likert Scale (0 = ‘the behaviour is
not observed’ – 4 = ‘the behaviour is observed and executed to a high standard’).
Following OPTION5 guidelines, these scores will be transformed to a 0–100 score.
Analysis of recorded
consultation
Discussion of patient preferences and
values
All values and preferences discussed during the consultation will be coded by using
a codebook that will be developed specifically for this study, distinguishing
between the contribution of the patient, relative (s) and caregiver. This codebook
will be (partly) based on the values and preferences that are distinguished in part 1
of the OnVaCT-project.
Analysis of recorded
consultation
Duration of the consultation The length of the consultation will be assessed by measuring the length of the
recorded consultation in minutes.
Analysis of recorded
consultation
Actual usage of the tool To analyse the actual usage of the tool, Google Analytics will be used to log the
number of website visits (i.e. the number of times someone visited/used the tool),
the time spent on the website (i.e. the accumulated time someone used the tool)
and the number and kind of pages viewed.
Tracking data at T1,
only in post-test
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and the consultation duration) and the actual usage of the
OnVaCT (which will be tracked by using Google
Analytics).
Sample size calculation
The sample size calculation is based on decisional conflict
as the primary outcome. Following literature, we assume a
mean decisional conflict score of 27 (sd = 12) in the pre-
implementation period [7]. To acquire an 80% power to
detect an effect size of .30 with an alpha-level of .05 (one-
sided), a total sample size of 276 patients is required (138
in the pre-test before the implementation of the OnVaCT
and another 138 after the implementation). The three par-
ticipating hospitals currently see approximately 400–500
new patients a year who consider participation in phase I
clinical trials. Based on previous research, we expect a
response rate of approximately 40%. We thus need
approximately 12months in the pre-test and another 12
months in the post-test to recruit the required number of
patients. We will start the pre-test 18months before the
implementation of the OnVaCT, and if needed, we can
spend another 18months for the post-test. Hence, the
inclusion of 276 participants based on the sample size
calculation is feasible.
Statistical analysis
All analyses regarding the evaluation of the OnVaCT will
be performed in the most recent version of IBM SSPS
Statistics. Descriptive statistics and frequency distributions
will be generated for the patients’ demographics and med-
ical disease characteristics. For the analysis of the main
and secondary outcome measures, an intention-to-treat
analysis will be used, thereby including patients who were
included in the post-test group (i.e. after the implementa-
tion of the OnVaCT with accompanying training) regard-
less of whether or not they used the OnVaCT.
For the analysis of decisional conflict, a one-sided t-test
will be performed between the pre- and post-test
measurements. Patient demographics, performance status,
health literacy and the level hope may be used as covari-
ates to correct for possible imbalance between the patients
from the two study periods (pre-test and post-test) by
means of regression analysis. In addition, a mediation
analysis will be performed using Structural Equation
Modelling (SEM) to calculate the direct effect of the use
of the OnVaCT on decisional conflict and to what extent
that effect was mediated by communication during the
consultation (i.e. the extent to which patients are involved
in the decision making process as measured with the
adapted Observer OPTIONMCC [44]; and the extent to
which patient values and preferences are discussed as
measured with a codebook we will develop). In the SEM
analysis, patient demographics, performance status, health
literacy, the sense of hope and the quality of life at baseline
may be used as covariates to correct for possible imbal-
ance between the patients from the two study periods
(pre- and post-test).
Secondary outcomes, e.g. the total score for the shared
decision making process during consultation, the discus-
sion of patients’ values and preferences by patients,
relatives and caregivers and the length of the consultation
will be compared between the two test periods using two-
sided t-tests. Again, the regression analysis may be used to
correct for possible differences in patient demographics,
performance status, health literacy and hope between the
patients from the two study periods (pre- and post-test).
Descriptive statistics will be generated for technology
acceptance and satisfaction with the tool, which are only
measured in the post-test.
Discussion
The importance of incorporating patient values in patient-
physician communication has received increased attention
recently. Over the years, value clarification methods or
exercises have been developed as part of a decision aid
[46]. The OnVaCT project however is developed from a
different perspective, using digital communication (serious
gaming), to help patients articulate their values and
perspectives related to their decisions for participation in
an early phase clinical trial and/or a palliative care trajec-
tory. By using the OnVaCT before the appointment with a
medical oncologist of an early phase clinical research unit,
patients are assumed to share and formulate their personal
values with their oncologist more easily, which in turn
may support oncologists in tailoring the information to
the patients’ needs. We aim to develop the OnVaCT as a
comprehensive package with a training module for oncol-
ogists to assist them in discussing patients’ results of the
OnVaCT. As the decisional conflict scale appears viable
for measuring the quality of end-of-life decision making
[47], a decrease in decisional conflict can be seen as an
improvement of patients’ decision making process, which
may contribute to an improved quality of life [8, 9].
We will use decisional conflict as our primary endpoint,
which is the most frequently used scale in studies aimed
at improving medical decision making [48]. For this end-
point, the timing of measurements is essential. However, a
scoping review revealed that thus far only few studies have
measured both the decision-making stage and decisional
conflict [49]. We have chosen to measure decisional
conflict 3 weeks after a patient’s initial consultation with a
medical oncologist. Patients often have a (telephone)
appointment with the medical oncologist or a nurse prac-
titioner about 1 week after the initial consultation to ask
for or confirm their decision regarding trial participation.
The 3 week time frame therefore offers most patients
sufficient opportunity to make a decision and to let that
decision sink in, but is, obviously, too early for patients to
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have already started treatment in an early phase clinical
trial. By analysing the communication process in the first
consultation that patients have with the medical oncolo-
gist regarding participation in such a trial and incorporat-
ing this into SEM analysis, this is one of the first studies
that is able to link the process during the consultation to
decisional conflict.
A longitudinal follow-up study is necessary to evaluate
the potential effects of the OnVaCT on a longer term than
3 weeks. Additionally, it seems important to integrate
patient-reported preferences along the entire cancer tra-
jectory, as patient preferences may change in relation to
treatment experiences, coupled with the impact on quality
of life [17, 50]. A longitudinal study could therefore also
reveal the effect of the experienced burden of trial partici-
pation, (potentially) exhausting logistics or, ultimately,
profiting from participation in a trial or not on decisional
conflict. Since the current study includes patients with
advanced cancer who are considering participation in
early phase clinical trials, both patients who eventually
chose to participate in an early phase clinical study and
those who chose not to participate will be included.
The OnVaCT study uses both qualitative and quantita-
tive research methods to develop and perform the initial
testing phase for a value clarification tool that is meaning-
ful for both patients and oncologists. This mixed-methods
approach offers the opportunity to build on in-depth
analyses to gain a better understanding of the underlying
processes of difficult and potentially life-changing choices
to create an OnVaCT that suits patients’ decision making
processes, but also to quantitatively evaluate the OnVaCT.
The OnVaCT (with training module) will already be
implemented in clinical practice during the evaluation of
the tool in the three largest centres for early phase clinical
research in the Netherlands (located in Rotterdam,
Utrecht, and Amsterdam), making it easy to continue
using the OnVaCT when it appears to be of value during
the evaluation. Additionally, studies regarding other (end-
of-life) decisions, which may pose a similar type of
decision conflict, may also benefit from the results of the
current project. Even though the benefit from treatment
may be known, and therefore more precise arguments pro
and contra treatment can be made, patients who are able
to identify and realize their personal values regarding
these treatments, could still benefit from less decisional
conflict and more attuned discussions with their oncolo-
gists regarding the choices they make.
If this project has its hypothesized positive outcome,
meaning that decisional conflict indeed seems to decrease
by using the OnVaCT, the project can be followed up in
different manners. For instance, regional hospitals could
be asked to participate and use the OnVaCT to aid in
decision making after “bad news” has been delivered on
the absence of regular treatment options, which could
help improve specific referral for early phase clinical trials.
As the use of the OnVaCT in peripheral hospitals provides
all eligible patients to consider their preferences regarding
participation in early phase clinical trials, patients who
come to the conclusion that participation is not suitable
for them, do not have to be referred to an early phase
clinical research unit at all. As only a specific selection of
patients who actually consider participating in early phase
clinical trials will be referred, the medical oncologists
could perhaps attune their consultations even better at
this particular population.
Challenges and limitations
The main challenge of this project concerns the feasibility
of timely reaching, informing, and inclusion of patients will-
ing to participate in the first interview or the first question-
naire. Referral time to an early phase clinical trial centre is
usually short (approximately 1 week). It is critical that there
is close contact between the clinical trial managers and the
executing researchers (NS and LL), so that patients can be
timely approached for planning and conducting an inter-
view or completion of the first questionnaire before the
initial consult about potential participation in an early
phase clinical trial takes place.
A first limitation of the current project is that although
our hypothesis that using the OnVaCT will decrease deci-
sional conflict, it is also possible that the opposite will be
the case. After all, when patients are asked to use the
OnVaCT, we may make them more aware of the choices
they have towards the end of their lives, which in turn
may cause them to think more about these choices and
lead to a different decision or increase their experienced
decisional conflict as a result. Additionally, all oncologists
whose consultations will be recorded, will be asked for
consent to make these recordings and may consequently
be made more aware of what and how they communicate
with their patients. This could mean that the oncologists
possibly already focus more on patient values during the
pre-test than they would do otherwise, which may cause a
bias in our pre-test. Nevertheless, being aware that patient
values should play a role in the consultations does not
necessarily mean that the consultations cannot still be
improved or personalized.
It is also important to realize that the pre-test post-test
study design could also cause another potential bias in the
current project due to the rapidly evolving cancer drug
developments, and patients’ perceptions about these (new)
drugs as a result. Previous studies have shown multiple
shifts in phase I oncology trials over (more than) a decade,
including (but not limited to) changes in the distribution
of cancer types among patients who participate in these
trials [51], patient characteristics and trial designs [52],
and decreased toxic death rates [53]. Since the start of the
pre-test and the end of the post-test are about 2.5 years
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apart (see Fig. 1), it may be assumed that shifts in phase I
oncology trials are less significant over the inclusion
periods of the present study.
Concluding remark
In short, this project will generate an OnVaCT that aims
to assist patients with advanced cancer for whom standard
treatment options are exhausted to clarify their values
facing a difficult end-of-life decision, e.g. the participation
in an early phase clinical trial. The OnVaCT may thus
help these patients to better determine their preferences
regarding experimental treatment. By sharing these results
with the medical oncologist, the communication during a
consultation may be better attuned to individual patient’s
needs and thereby support him or her in the decision
whether or not to participate in an early phase clinical
trial, probably resulting in less decisional conflict.
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